NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he detailed the company's nanoviricide technology and the progress of its lead drug candidate, NV-387. The interview emphasized the platform's ability to prevent viral escape, function independently of patient immune status, and provide broad-spectrum antiviral coverage across all age groups, from infants to the elderly.
Dr. Diwan highlighted that NV-387 has demonstrated efficacy in lethal animal models against multiple unrelated viruses, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles. The candidate has completed a Phase I clinical trial with no reported adverse events, establishing a favorable safety profile. A Phase II clinical trial for NV-387 targeting MPox is poised to begin in the Democratic Republic of Congo following regulatory clearance. This positions NV-387 as a potential empirical therapy for acute respiratory and other viral infections, with an estimated market opportunity exceeding $17 billion by 2030.
The nanoviricide platform is designed to mimic host cell receptors, enabling the drug to bind to viruses and neutralize them without relying on the patient's immune response. This mechanism allows for potential use in immunocompromised patients, a significant advantage over traditional antiviral therapies. Dr. Diwan noted that the technology could be adapted to target specific viruses by altering the ligand on the nanomicelle, offering a customizable approach to antiviral treatment.
NanoViricides is a clinical-stage company focused on developing nanomaterials for antiviral therapy. The company's drug candidates are based on intellectual property and know-how licensed from TheraCour Pharma, Inc. The company's lead candidate, NV-387, is being developed for RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPox and Smallpox. Another advanced candidate, NV-HHV-1, targets shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The company also has a pipeline of drugs against various viral diseases, including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola. NanoViricides holds exclusive perpetual licenses for several drugs with specific targeting mechanisms for human viral diseases. However, the company cautions that drug development is lengthy and requires substantial capital, and there is no assurance that any of its candidates will prove safe and effective in clinical trials.
For more information, visit the company's newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/EqHoV.
